Affinity Asset Advisors, LLC 13F Holdings · Q2 2026
Affinity Asset Advisors, LLC reported 103 securities worth $2.21B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: ROIV (6.00%), APGE (5.92%), SYRE (5.13%). Among its top 25 positions this quarter: 2 new, 12 added, 9 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ROIV | ROIVANT SCIENCES LTD | $132.7M | 6.00% | 3.8M | Added |
| 2 | APGE | APOGEE THERAPEUTICS INC | $131.0M | 5.92% | 987,000 | Trimmed |
| 3 | SYRE | SPYRE THERAPEUTICS INC | $113.6M | 5.13% | 1.3M | Hold |
| 4 | ERAS | ERASCA INC | $96.2M | 4.35% | 5.2M | Trimmed |
| 5 | XENE | XENON PHARMACEUTICALS INC | $96.3M | 4.35% | 1.6M | Trimmed |
| 6 | ALKS | ALKERMES PLC | $72.0M | 3.26% | 1.4M | Added |
| 7 | INSM | INSMED INC | $69.3M | 3.13% | 650,000 | Added |
| 8 | MRNA | MODERNA INC | $68.3M | 3.09% | 975,000 | Added |
| 9 | PRAX | PRAXIS PRECISION MEDICINES I | $61.9M | 2.80% | 185,000 | Added |
| 10 | ORKA | ORUKA THERAPEUTICS INC | $56.2M | 2.54% | 590,000 | Added |
| 11 | ANAB | ANAPTYSBIO INC | $55.8M | 2.52% | 826,109 | Trimmed |
| 12 | AVTX | AVALO THERAPEUTICS INC | $53.6M | 2.42% | 2.9M | Added |
| 13 | CYTK | CYTOKINETICS INC | $46.9M | 2.12% | 550,000 | Trimmed |
| 14 | RVMD | REVOLUTION MEDICINES INC | $46.8M | 2.12% | 250,000 | Added |
| 15 | ABVX | ABIVAX SA | $44.0M | 1.99% | 330,000 | Trimmed |
| 16 | TRAX | FIRST TRACKS BIOTHERAPEUTICS | $40.9M | 1.85% | 2.0M | New |
| 17 | DNTH | DIANTHUS THERAPEUTICS INC | $39.0M | 1.76% | 400,000 | Hold |
| 18 | STRO | SUTRO BIOPHARMA INC | $38.9M | 1.76% | 1.2M | Added |
| 19 | NUVL | NUVALENT INC | $34.0M | 1.54% | 275,000 | Trimmed |
| 20 | TRVI | TREVI THERAPEUTICS INC | $33.6M | 1.52% | 1.8M | Trimmed |
| 21 | ARKG | ARK ETF TR | $31.5M | 1.43% | 750,000 | New |
| 22 | OVID | OVID THERAPEUTICS INC | $27.3M | 1.23% | 10.1M | Trimmed |
| 23 | LXEO | LEXEO THERAPEUTICS INC | $27.0M | 1.22% | 5.8M | Added |
| 24 | CLDX | CELLDEX THERAPEUTICS INC NEW | $26.0M | 1.18% | 700,000 | Added |
| 25 | BLTE | BELITE BIO INC | $25.4M | 1.15% | 165,000 | Added |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR